Introduction: Cardiac amyloidosis is one of the several systemic manifestations of amyloidosis. It is a relatively uncommon disease. Patients with cardiac amyloidosis clinically present with rapidly progressive heart failure. Case Presentation: We present a case of 64-year-old man with multiple episodes of chest discomfort accompanied sometimes with dyspnoea for the past several months. A non-specific ST-T changes with low voltage limb leads on ECG, a diastolic dysfunction with preserved ejection fraction on echocardiography, increased troponin and BNP, increased serum λ/κ light chain ratio led us to highly suspect amyloidosis with cardiac involvement. Abdominal fat pad biopsy confirmed the amyloid type change of subcutaneous fat, with immunohistochemistry revealing Lambda positive. After confirmed diagnosis of primary systemic amyloidosis with cardiac involvement, patient completed six cycles of chemotherapy with bortezomib and dexamethasone. The patient showed significant improvements after chemotherapy and supportive therapy. Conclusion: Amyloidosis is relatively fatal disease. Patients often have a short life expectancy after symptom onset. Early diagnosis is crucial to proper management and better prognosis.
Endomyocardial biopsy is gold standard for diagnosing cardiac amyloidosis.
However, it is more invasive and much difficult to perform. Hence, abdominal fat pad biopsy is preferred over endomyocardial biopsy to establish definite diagnosis of systemic amyloidosis [4] . We here present a case of primary systemic amyloidosis with cardiac involvement and clinical manifestation of multiple episodes of chest discomfort.
Case Report
A 64-year-old male smoker presented to our hospital with complains of multiple episodes of chest discomfort which sometimes is accompanied with dyspnoea months of chemotherapy and other supportive measures, patient had significant symptomatic relief with chest discomfort and dyspnoea. The peripheral edema was also reduced compared with presentation at admission.
Discussion
Amyloidosis is a multisystem disorder due to deposition of insoluble amyloid fibrils that have characteristic β-pleated sheet configuration and produces apple-green birefringence under polarized light when stained with Congo red dye [5] . Amyloid deposition in the heart results in cardiac amyloidosis, clinically presents with rapidly progressive heart failure because of restrictive cardiomyopathy, and sometimes presents with typical angina due to amyloid deposition in arterial vessel wall causing progressive luminal narrowing and hence myocardial ischemia and impairment [7] . Anish et al. described a case with cardiac amyloidosis presenting as recurrent acute coronary syndrome without coronary artery obstruction [8] . Diagnosis of amyloidosis relies on clinical awareness of the disease, clinical features, blood and tissue analysis, and positive findings on biopsy.
For patients with heart involvement, the most common clinical feature is diastolic heart failure, which is manifested as progressive dyspnea. In our case, patient complained of multiple episodes of chest discomfort from last 4 months, abdominal fat pad biopsy and immunohistochemisty. Some cases have also reported pharyngeal symptoms related to amyloidosis causing dysphagia [9] . So the clinicians should pay more attention to the systemic disorders such as nephropathy, skin damage, macroglossia, sympathetic or vagus nerve disease e.g. is also useful for diagnosis, and is preferred because of its non-invasive nature prior to any invasive procedure [11] . Troponin and BNP/NT-proBNP reflects high filling pressures, and are highly useful in diagnosis and assessment of prognosis of AL amyloidosis [12] . According to Mayo Clinic staging, patients are stratified into three groups; high risk group if both biomarkers are increased, intermediate risk group if at least one biomarker is above the cut off value and low risk if both biomarkers are below cut off values [13] . In our case, we found highly increased BNP and troponin at diagnosis, which indicated we were dealing with a patient of high risk. Based on Mayo Clinic staging, those in high risk group have median survival of 7 -8 months.
Management of systemic amyloidosis is done by stopping the production of abnormal light chains by plasma cells and supportive care provided to decrease symptoms and support organ function [14] . Chemotherapy strategy includes dexamethasone with either melphalan or cyclophosphamide or an immunomodulatory (thalidomide, lealidomide or proteasome inhibitor bortezomib) [15] .
The response to treatment is assessed by measuring free light chains in the [17] . In our case, after starting chemotherapy, patient's heart failure symptoms relieved. The serum free light chain level was also decreased. It has been more than six months of confirmed diagnosis and patient condition has significant improvement.
Conclusion
Amyloidosis is uncommon, yet relatively fatal disease. 
